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Historically, adrenocorticotropic hormone was used as a first-line treatment for infantile spasms; however, there has been increasing use of topiramate as initial therapy. Here, we report a retrospective study of adrenocorticotropic hormone (ACTH) and topiramate as initial treatment for infantile spasms. The neurology patient database at the Children's Hospital of Philadelphia was searched using the International Classification of Diseases, Ninth Revision code for infantile spasms, and 50 patients were randomly chosen for chart review. We identified 31 patients receiving either adrenocorticotropic hormone or topiramate monotherapy (adrenocorticotropic hormone n ¼ 12, topiramate n ¼ 19) as a first-line treatment for infantile spasms. A total of 26 patients were symptomatic and 5 cryptogenic. Six patients treated with adrenocorticotropic hormone had resolution of clinical spasms and hypsarrhithmia within a month, but 3 relapsed. Of the 19 patients treated with topiramate, 4 patients eventually, though over a period of 0, 1, 8, or 69 months, had resolution of spasms and hypsarrhythmia.
Keywords: infantile spasms; ACTH; topiramate T he American Academy of Neurology and the Child Neurology Society supported the use of adrenocorticotropic hormone (ACTH) for treating infantile spasms, though the dose and duration of treatment was not specified. 1 They also suggested that vigabitrin might be effective. The efficacy of ACTH for resolution of clinical spasms has varied from as low as 33% to as high as 100%,with relapse rates of 8% to 50%. [2] [3] [4] [5] Resolution of hyppsarrhythmia onthe electroencephalography (EEG) with ACTH also varied with rates as low as 21% and as high as 100%. In most studies, cryptogenic patients faired better than symptomatic patients. There are, however, numerous other treatments that have been used to various extents for treating infantile spasms including B6, nitrazepam, valproic acid, prednisone, leviteracetam, zonisamide, and topiramate. Although these treatments have shown efficacy, they have not been studied in a blinded fashion and are frequently used as a second-line treatments when ACTH or vigabitrin has failed.
Topiramate has been shown in several studies to have efficacy up to 45% for the resolution of infantile spasms. [12] [13] [14] [17] [18] [19] Most of the studies have looked at patients that have failed a previous drug, such as ACTH or vigabatrin, prior to receiving topiramate. [17] [18] [19] [20] [21] [22] Other studies have treated patients with multiple medications concurrent with topiramate for their infantile spasms. 13 The studies to date have suggested that topiramate is tolerated though lethargy, weight loss, anorexia, and anhydrosis have been reported. [21] [22] [23] Our study was focused on determining whether topiramate is being used in clinical practice for the initial treatment for infantile spasms; identifying whether there is a treatment bias in patient selection for ACTH or topiramate; and determining how often patients have the resolution of both clinical spasms and hypsarrhythmic EEG following treatment.
Methods

A retrospective chart review was performed on patients diagnosed with infantile spasms between 2002 and 2005 at the
Children's Hospital of Philadelphia. A total of 50 randomly chosen patient charts were obtained for review. Those receiving either ACTH or topiramate as the initial treatment for infantile spasms had further data analysis. Charts were screened for demographics, EEG, clinical findings, etiology, medications prescribed, doses, remission duration, treatment discontinuation due to side effects, and qualitative clinical data as described. Infantile spasms remission was defined as a total cessation of both clinical and hypsarrhythmia features of infantile spasms. Presence of hypsarrhythmia and initial treatment with ACTH or topiramate were required for inclusion. Initial treatment was defined as first medication prescribed following diagnosis. Relapse was defined as recurrence of clinical spasms and/or the hypsarrhythmia on the EEG following a resolution of both clinical spasms and hypsarrhythmia at an office visit. Clinical data were organized in a database and quantitatively analyzed using unpaired t test with Welch's correction and Wilcoxon analysis for the treatment duration in responders.
Results
Demographics
A total of 31 patients (15 males and 16 females) met the inclusion criteria. All patients were younger than 21 months at the time of initial treatment. The mean age of initial treatment was 4.68 months (range 2 to 7.5 months, median 5 months) for ACTH and 8.05 months (range 0 to 21 months, median 6.0 months) for topiramate. The difference in mean age between the 2 initial treatment groups was statistically significant, as calculated by an unpaired t test with Welch's correction (P ¼ .032). In all, 3 patients from the ACTH initial treatment group and 2 patients from the topiramate initial treatment group had cryptogenic infantile spasms, while the remaining patients in both the groups possessed a combination of genetic and clinical findings consistent with a symptomatic etiology for their infantile spasms (see Tables 1 and 2 ). The duration of clinical spasms prior to treatment did not differ between the treatment groups. A total of 15 patients exhibited flexor and 4 extensor spasms in the topiramate initial treatment group, while 8 flexor and 3 extensor spasms were observed in the ACTH treatment group. For 1 patient, the flexor versus the extensor spasm activity was not recorded.
A total of 14 patients were not included for further analysis. Two patients were excluded for receiving ACTH and topiramate simultaneously as their initial treatment, 4 for receiving vigabatrin as their first treatment, 1 for receiving phenobarbital and vitamin B6 as their first treatment, 1 for a nonhypsarrhythmic EEG, 1 for a change in diagnosis from infantile spasms to another condition, and 5 for missing pertinent chart information to confirm the diagnosis or initial treatment.
Treatment
A total of 12 patients were initially treated with daily ACTH and 19 with topiramate (see Table 2 ). The mean highest doses were 146 U/m 2 /d (range 88 to 180 U/m 2 /d) of ACTH and 14.35 mg/kg/d (range 1.3 to 35.1 mg/kg/d) of topiramate (Table 3 ).
Outcome
Of the 12 patients treated with ACTH, 6 (50%) had resolution of their clinical spasms and hypsarrhythmic EEG within a few weeks of starting treatment. In all, 3 of the patients had a recurrence of their infantile spasms and hypsarrhythmic EEG between 2 and 6 months later. Of the 19 patients treated with topiramate, 4 eventually achieved resolution of their spasms and hypsarrhythmic EEG. The amount of time to achieve permanent resolution of clinical spasms and hypsarrhythmic EEG was less than 1 month in all the patients on ACTH alone and 19.5 months average (range 0 to 69 months) on topiramate. Three of 12 (25%) patients treated initially with ACTH and 4 of 19 (21%) treated with topiramate eventually achieved permanent infantile spasms remission (see Table 4 ).
A total of 9 patients failed ACTH including 3 with temporary remission, all received additional treatment regimens, and 4 eventually achieved permanent infantile spasms remission. In all, 7 were treated with topiramate as their second medication and 1 had permanent resolution of infantile spasms. Of the 15 patients that failed topiramate initially, 9 were given additional treatment for their infantile spasms, and 3 eventually achieved permanent infantile spasms remission. Seven of the 8 were treated with ACTH as their second medication and 2 of the 7 achieved permanent remission.
Side Effects
Charts were reviewed for documented side effects; only 2 patients initially treated with topiramate had documented side effects (appetite loss, tremors, and lethargy). In neither case did the side effects result in stopping treatment. None of the patients on ACTH had documented side effects and none had premature medication withdrawal.
Discussion
Here, we describe a retrospective study of patients treated for infantile spasms at the Children's Hospital of Philadelphia from 2002 to 2005. We find that topiramate was being widely used as a first-line treatment for infantile spasms in a large group academic practice. Topiramate monotherapy was the most common first-line treatment for infantile spasms, ACTH monotherapy second, and vigabatrin third. Because of the retrospective nature of the study, likely selection biases and variability within the treatment regimens, the findings are best interpreted as a description of the use of ACTH and topiramate for infantile spasms in a clinical setting. We found a selection bias toward younger patients receiving ACTH treatment compared to topiramate but other parameters, such as symptomatic versus cryptogenic, did not clearly stratify with treatment regimen. Most patients were symptomatic and neither ACTH nor topiramate succeeded in the longterm resolution of clinical spasms and hypsarrhythmic EEG in the majority of patients. The range of maximum doses of ACTH and topiramate and the corresponding titration schedules reflect the diversity of approaches reported in the literature. 12, 17, 18, 20 Side effect reporting is limited to those the treating physician chose to document and were those previously reported for topiramate, appetite loss, tremors, and lethargy, but no patient appeared to have either medication stopped for side effects alone. There was a wide range of topiramate dosing, 1.3 to 35 mg/kg/d, with an average of 14 mg/kg/d similar to that achieved in prior studies. 11, 12 Two of the patients that responded to topiramate in 1 month or less did so at low doses, 1.3 and 3.4 mg/kg/day, raising the possibility of an extremely treatment responsive population.
The majority of patients in both the treatment groups had symptomatic infantile spasms with developmental delay, abnormal neurologic exam, and/or abnormal magnetic resonance imaging (MRI) findings. Only 5 of the 32 patients were classified as cryptogenic at the time of therapy initiation. Of the 12 patients treated with ACTH, 6 had resolution of their spasms and hypsarrhythmia within the first month of treatment but 3 patients had recurrence after 2, 2.5, and 6 months. The response rate to ACTH, while low, is similar to other studies showing a 50% or less clinical response in symptomatic patients initially with a 20% relapse rate and only *20% to 30% resolution of hypsarrhythmia on EEG. 3, 24 The long-term efficacy of topiramate was 4 of 19 lower than the 45% reported in 1 study but similar to the 20% in a more recent study. 11, 12 In addition to the reported monotherapy patients, 2 patients started within days on both topiramate and ACTH though neither had resolution of their spasms on this regimen. Interestingly, of those patients that failed the initial drug treatment, many were crossed over from topiramate to ACTH (2 of 7 with eventual permanent remission) or ACTH to topiramate (1 of 7 with eventual permanent remission) as their second-line treatment in either group. As a second-line treatment, ACTH and topiramate had relatively similar, poor rates of infantile spasms resolution for these small groups of patients.
The major difference in the use of ACTH and topiramate was a longer treatment course in the topiramate treatment group. Topiramate responders had resolution of their spasms and hypsarrhytmia 0, 1, 8, and 69 months versus less than a month for every patient in the ACTH treatment group. The increased duration for topiramate treatment points to the willingness of the treating physicians to extend topiramate therapy, which did not occur in ACTH treatment. Because infantile spasms are felt to be an epileptic encephalopathy, there is concern for worse cognitive and behavioral outcome following a delay in the resolution of spasms and hypsarrhythmia seen in the topiramate treatment group. Supporting this concern is the report of patients with cryptogenic infantile spasms having a better cognitive outcome following treatment with ACTH than vigabitrin. 25 Our findings highlight the significant use of topiramate as the initial treatment strategy for infantile spasms in an academic child neurology practice. A treatment bias toward treating younger patients with ACTH and older patients with topiramate was present at our center. The patients reported in this study were treated prior to the recent dramatic escalation in the cost of ACTH, which may further decrease its use. In summary, neither ACTH nor topiramate was highly efficacious in our mostly symptomatic patient population but overall ACTH had a rapid resolution of spasms and hypsarrhythmia.
